The Advanced Research Projects Agency for Health (ARPA‑H) awarded up to $21.8 million to Georgia Tech to develop a first‑of‑its‑kind therapeutic intervention for lymphatic diseases. The program will support translational work bridging engineering, biomaterials and molecular therapeutics aimed at restoring lymphatic function. Georgia Tech researchers will use the funding to accelerate preclinical development and to build an interdisciplinary pipeline that spans device design, delivery systems and biologic modulation of lymphatic tissue. ARPA‑H’s investment signals agency interest in high‑risk, systems‑level interventions for underserved indications and reflects growing federal support for innovative, cross‑discipline programs that aim to de‑risk late‑stage translational milestones. For translational researchers and startups: the award creates collaboration opportunities with an academic engineering powerhouse and may catalyze spinouts or industry partnerships focused on lymphatic disease diagnostics and therapeutics.